Process scheme to improve divalent metal salts removal from mono ethylene glycol (MEG)
US-9790153-B2 · Oct 17, 2017 · US
US11779859B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-11779859-B2 |
| Application number | US-202117546305-A |
| Country | US |
| Kind code | B2 |
| Filing date | Dec 9, 2021 |
| Priority date | Dec 9, 2020 |
| Publication date | Oct 10, 2023 |
| Grant date | Oct 10, 2023 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
The present invention is directed to a method of producing active pharmaceutical ingredients (APIs). The method includes subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor. The method includes concentrating the API precursor in the reactant stream using at least one membrane. The method includes carrying out a reaction in a membrane reactor. The method includes separating the API precursor from the reaction stream using a separator. The method includes crystallizing the API precursor using a crystallizer to produce APIs.
Opening claim text (preview).
The invention claimed is: 1. A method of producing active pharmaceutical ingredients (APIs), comprising: (a) subjecting a reaction mixture with an API precursor to solvent extraction to produce a reactant stream with the API precursor; (b) concentrating the API precursor in the reactant stream using at least one membrane; (c) carrying out a reaction in a membrane reactor; (d) separating the API precursor from the reaction stream using a separator; and (e) crystallizing the API precursor using a crystallizer to produce APIs, wherein at least one of a reactor for performing step (a), the separator of step (d), or the crystallizer of step (e) is a membrane-based device. 2. The method of claim 1 , comprising heating, cooling, and/or quenching of solutions containing active pharmaceutical ingredients using solid hollow fiber heat exchangers. 3. The method of claim 2 , wherein the heat exchangers are membrane-based. 4. The method of claim 1 , comprising removing impurities from organic process streams using membrane adsorbers.
Hollow fibre modules · CPC title
Pervaporation · CPC title
General arrangements of crystallisation plant, e.g. flow sheets · CPC title
from solutions · CPC title
Applications, solvents used · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.